Information Provided By:
Fly News Breaks for February 26, 2020
Feb 26, 2020 | 06:16 EDT
BTIG analyst Sean Levin initiated coverage of Cerus with a Buy rating and $7 price target. The analyst cites the company's position as the "only pathogen reduction platform to have FDA approval and a Class III CE Mark for platelets and plasma." Levin further cites a large blood transfusion market of 117M blood donations globally per year and expects pathogen reduction to become standard of care for platelets in the U.S. following the release of final guidance from the FDA.
News For CERS From the Last 2 Days
There are no results for your query CERS